Medicine pack check sheet

Source-linked reading points

• The 2024 FDA label lists 10, 20, 30 and 40 mg tablets, and an oral suspension of 10 mg/5 mL that the label states was not then marketed. Mg and mg/5 mL label tablet strength and liquid concentration respectively; they cannot be self-converted, substituted or adjusted by tablet count or millilitres from experience.
• This DailyMed image corresponds only to a historical PAXIL 20 mg tablet label. Package artwork, tablet colour or imprint are checking clues, not tools to authenticate a medicine, and cannot prove that another market, strength, suspension or paroxetine product is the same.
• The label identifies other medicines that affect serotonin, clotting or metabolism, and MAOI-related transitions, as issues requiring professional review. Give the pharmacist or prescribing team all prescription medicines, non-prescription products, supplements and recent changes; do not self-combine, alternate or substitute because products share an antidepressant class or similar name.
• The FDA label notes that discontinuation may cause adverse reactions and that a professional should manage gradual reduction. With a wish to stop, a switch, missed use, sudden mood or behaviour change, or an urgent safety risk, contact the prescribing team and use local emergency support; do not abruptly stop from remaining medication, a package image or a webpage.